It lowers uric acid by inhibiting xanthine oxidase, helping prevent crystal formation and future complications. It does not provide pain relief during an acute gout attack.
Adults with gout, recurrent uric acid stones, or a high risk of uric acid buildup during cancer treatment may be prescribed Allopurinol.
The active ingredient is allopurinol, supplied as oral tablets. The strength determines how much active ingredient each tablet provides, while the appropriate daily amount depends on the individual treatment plan.
Generic allopurinol tablets contain the same active ingredient used for urate lowering. Intravenous allopurinol is a hospital-administered formulation used in selected urgent clinical settings, including some cases of tumour lysis syndrome; it is different from oral tablets.
Allopurinol is used to reduce uric acid in several clinical situations. The main uses include gout prevention, uric acid kidney-stone prevention, and prevention of uric acid accumulation during tumour lysis syndrome.
| Condition | How Allopurinol helps | Typical clinical role |
|---|---|---|
| Gout | Lowers uric acid and reduces crystal formation | Long-term prevention of attacks and joint damage |
| Uric acid kidney stones | Reduces uric acid production | Prevention when stones are caused by uric acid |
| Tumour lysis syndrome | Limits uric acid formation after rapid cell breakdown | Prevention before or during selected cancer treatments |
Gout causes sudden, severe joint pain, often in the big toe. Uric acid crystals trigger inflammation inside and around the joint. Allopurinol lowers the urate level that supports crystal formation, so it is used daily for prevention rather than immediate relief.
Treatment aims to reduce serum urate sufficiently for crystals to dissolve gradually. NICE recommends a treat-to-target approach, with serum urate monitoring and dose adjustment according to the individual response [2].
When cancer cells are destroyed quickly, they release purines that can be converted into uric acid. A rapid rise in uric acid may contribute to kidney injury and other metabolic abnormalities associated with tumour lysis syndrome.
Allopurinol may be started before chemotherapy or another cancer treatment when the clinical risk is significant. Hospital teams may combine it with blood tests, intravenous fluids, and other urate-lowering treatment according to the risk level.
Not every kidney stone is caused by uric acid. Allopurinol is relevant when testing identifies uric acid stones or excessive uric acid production as a contributing factor.
Hydration, urine chemistry, kidney function, and the stone composition guide prevention. A person with calcium-based stones may need a different plan.
This treatment is not appropriate for someone with a previous serious hypersensitivity reaction to allopurinol. It also requires specialist review when severe kidney disease, significant liver disease, blood-count abnormalities, or a history of severe drug allergy is present.
This treatment is NOT for you if you have had a serious hypersensitivity reaction to allopurinol or develop warning signs requiring urgent assessment.
The combination with Allopurinol is not automatically forbidden, but a new rash, fever, facial swelling, or feeling unwell requires prompt medical attention.
People of Han Chinese, Korean, or Thai ancestry may have a higher frequency of the HLA-B*58:01 genetic variant, which is associated with severe allopurinol hypersensitivity. Pharmacogenetic guidance supports considering testing before treatment in high-risk populations, while local clinical policy and the person’s background determine whether screening is arranged [4].
Allopurinol inhibits their breakdown and can cause dangerously high exposure unless the combination is specifically managed with major dose reduction and close monitoring [3].
Digestive symptoms, headache, drowsiness, or a mild skin rash can occur with Allopurinol. Many people tolerate long-term treatment, though tolerability can change after a dose increase or when kidney function changes.
The most serious concern is a severe hypersensitivity reaction. Warning symptoms include:
These symptoms can indicate a serious skin, liver, kidney, or systemic reaction. Allopurinol should be stopped and urgent medical assessment obtained when these signs appear.
A mild gout flare is different from an allergic reaction. A hot, painful joint without a widespread rash may represent gout activity, while a new generalised rash requires a different level of concern.
Kidney impairment can increase exposure to Allopurinol and its active metabolite. Older adults may therefore need a cautious starting plan and gradual adjustment. Liver disease, dehydration, and multiple interacting medicines also affect clinical decisions.
Allopurinol is a xanthine oxidase inhibitor. Xanthine oxidase is the enzyme that helps convert purines into uric acid. By reducing this enzyme activity, Allopurinol lowers the amount of uric acid circulating in the blood and reduces the chance of uric acid crystals forming in joints or the urinary tract [1].
Purines are natural compounds found in many foods and in human cells. The body breaks them down through several stages, with xanthine oxidase contributing to the final production of uric acid. Allopurinol reduces this production rather than removing existing crystals immediately.
Uric acid is a waste product created when the body breaks down purines from food and body tissues. When blood uric acid remains high, crystals may collect in joints, causing gout, or form uric acid stones in the urinary tract.
Allopurinol belongs to the xanthine oxidase inhibitor class, also called the XOI class. Its uric-acid-lowering effect is dose-dependent, but the appropriate dose varies with kidney function, age, treatment response, and the strength prescribed.
Allopurinol is not an analgesic. It does not relieve the pain, swelling, or redness of an acute attack. Anti-inflammatory treatment is used for those symptoms when clinically appropriate.
Several practical errors can make treatment appear ineffective or increase avoidable risk:
Another easy mistake is confusing prevention with acute treatment. Allopurinol reduces future urate exposure; it does not numb an inflamed joint within hours.
Allopurinol is an oral, single-ingredient uric acid-lowering treatment that works by inhibiting xanthine oxidase. It differs from treatments intended for rapid relief of acute gout pain because its role is long-term prevention of uric acid crystal formation and accumulation.
In clinical practice, doctors usually frame Allopurinol as a long-term urate-lowering treatment rather than a tablet for occasional symptoms. The goal is sustained urate control, not simply feeling better between attacks.
Clinicians also expect the starting dose and later adjustments to differ between patients. Kidney function, serum urate, age, other medicines, flare frequency, and the presence of tophi all influence the plan. The appropriate amount is not identical for everyone.
The first weeks can be confusing because flares may occur before the full preventive benefit is established. A doctor may use colchicine, prednisone, or an anti-inflammatory medicine during this period, then reassess the plan through symptoms and blood-test results.
The European Medicines Agency and Medsafe emphasise the importance of recognising hypersensitivity reactions and reviewing the patient’s clinical risk factors before and during therapy [5].
Allopurinol can cause a rash, and a new rash must be taken seriously because rare hypersensitivity reactions can become severe. Stop further doses and obtain urgent medical assessment if the rash is widespread or accompanied by fever, mouth sores, facial swelling, blisters, peeling skin, or feeling unwell. The HLA-B*58:01 association is recognised in pharmacogenetic guidance published by CPIC . CPIC guidance (2013) supports considering this genetic risk before treatment.
There is no single universally superior time of day. Taking it after a regular meal, often breakfast, can help some people remember it and may reduce stomach upset. The key clinical requirement is consistent daily use at the prescribed frequency, with timing adjusted if another medicine creates a specific interaction. NICE guidance (2022) supports consistent daily dosing within an individual treatment plan.
Allopurinol is designed for regular urate lowering, not short-term relief after one tablet. Its clinical benefit depends on repeated dosing, steady exposure, and gradual adjustment until the serum urate target is reached. NICE guidance on gout management describes ongoing monitoring and dose adjustment rather than judging treatment by the effect of a single dose . NICE guidance (2022) supports this treat-to-target monitoring approach.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Starting urate-lowering therapy can temporarily increase the risk of gout flares. The changing urate concentration may mobilise crystals from tissues, even though the long-term direction is beneficial.
Colchicine is commonly used in a low preventive dose during the early months of Allopurinol treatment. Prednisone may be selected when colchicine or anti-inflammatory medicines are unsuitable. Ibuprofen can treat inflammation and pain in some adults, but it is not suitable for everyone and does not replace preventive therapy.
Colchicine requires careful dosing because excessive exposure can cause serious toxicity, especially with kidney disease or interacting medicines. Ibuprofen may aggravate stomach ulcers, kidney impairment, fluid retention, or cardiovascular disease. Prednisone can affect blood glucose, mood, blood pressure, and infection risk.
Rotorua, took Allopurinol daily for several months after repeated big-toe attacks. His urate results improved, but he experienced two flares early in treatment and initially thought the tablets were making his gout worse. After preventive anti-inflammatory treatment was added, the flares settled.
Blenheim, had been using Allopurinol for recurrent gout and found the routine easy once he linked it with breakfast. He reported mild stomach discomfort during the first week, which improved when he took the tablet with food and water.
Napier, had kidney impairment and needed a slower dose adjustment than a relative with gout. He felt disappointed that pain did not disappear immediately, then understood that the tablet was reducing future attacks rather than treating the current one.
Lower Hutt, stopped treatment after feeling better and had another flare several months later. Restarting required a new clinical review, and he later used a daily reminder to avoid repeating the interruption.
Greymouth, developed a widespread itchy rash shortly after starting treatment. He stopped taking further tablets and obtained urgent assessment; the episode made him more attentive to early skin symptoms with any new medicine.
